Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 02/08

20080051556 - Novel ptp-20, pcp-2, bdp1, clk, and sirp proteins and related products and methods: Nucleic acid molecules encoding full length PTP20, PCP-2, BDP1, mCLK2, mCLK3, mCLK4, and SIRP polypeptides, portions of such nucleic acid molecules, nucleic acid vectors containing such nucleic acid molecules, recombinant cells containing such nucleic acid vectors, polypeptides purified from such recombinant cells, antibodies to such polypeptides, and methods of identifying... Agent: Foley And Lardner LLP Suite 500

20080051555 - Support having affinity for antibody: A support having an affinity for an antibody characterized in that the carboxy end of a protein or a peptide, which is capable of binding to an antibody molecule, is immobilized via an amide bond mediated by a linker sequence to an insoluble support having a primary amino group. This... Agent: Morgan Lewis & Bockius LLP

20080051557 - Stable analogs of peptide and polypeptide therapeutics: The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080051558 - Method of preparing bivalirudin: The present invention relates to a novel solid phase peptide synthesis method for Bivalirudin. This method contains following steps: serving Trityl Chloride Resin, 4-Methyltrityl Chloride Resin, 4-Methoxytrityl Chloride Resin, or 2-Cl Trityl Chloride Resin, or attaching of Wang Resin as a start raw material); according to general solid phase peptide... Agent: Raymond Y. Chan

20080051559 - Mt-sp1 polypeptides: This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and... Agent: Wilson Sonsini Goodrich & Rosati

20080051560 - Regulation of gene expression by protein methylation: The invention relates to the cDNA and deduced amino acid sequence of the Coactivator Associated arginine (R) Methyltransferase protein, CARM1. A method is described for the use CARM1 to regulate gene expression in vivo. CARM1 has also been used to methylate arginine residues of histones, synthetic peptides, and other proteins.... Agent: Foley & Lardner LLP

20080051561 - Residual solvent extraction method and microparticles produced thereby: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080051562 - Thrombomodulin derivatives and conjugates: The transmembrane human protein thrombomodulin (TM), as a critical regulator of the protein C pathway, represents the major anticoagulant mechanism that is operative in both normal and injured blood vessels under physiologic conditions in vivo. Compositions and methods are disclosed relating to thrombomodulin derivatives and conjugates, including methods for site-specific... Agent: Greenlee Winner And Sullivan P C

20080051563 - Fc variants with increased affinity for fcyriic: The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20080051564 - Delivery of pharmaceutical agents via the human insulin receptor: A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human organs and tissue that express the HIR. The humanized murine antibody is especially well suited for delivering neuropharmaceutical... Agent: Quine Intellectual Property Law Group, P.C.

20080051565 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific... Agent: Robins & Pasternak

20080051566 - Method for separating lignin from a lignin containing liquid/slurry: A method for precipitating (separation) of lignin, using small amounts of acidifying agents, whereby a lignin product or an intermediate lignin product is obtained which can be used as fuel or chemical feed stock (or as a chemical or a raw material for further refining), from a lignin containing liquid/slurry,... Agent: Young & Thompson

20080045693 - Novel flea saliva protein: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and... Agent: Sheridan Ross PC

20080045694 - Preparation of solid phase bound peptides or pnas: The invention relates to a process for the preparation of at least one solid phase bound peptide. PNA or a chimera.... Agent: Birch Stewart Kolasch & Birch

20080045695 - Fusion protein suitable to be expressed high effectively and the production method thereof: The present invention provides a novel fusion protein suitable to be expressed high effectively and the production method thereof. The structure of the fusion protein is A-C1-K-(B-C2-K)n-D, wherein A is the upstream peptide; each of C1 and C2 is independently short peptides having 20-40 amino acids in length and containing... Agent: Merchant & Gould PC

20080045697 - Crystal structure of crig and c3b:crig complex: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the... Agent: Heller Ehrman LLP

20080045696 - Dna molecules encoding l-glutamate-gated chloride channels from rhipicephalus sanguineus: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus... Agent: Judy Jarecki-black, J.d., Ph.d.

20080045698 - Mammalian receptor proteins; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof Antibodies, both polyconal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080045700 - Canine cd20 compositions: The invention provides canine CD20 nucleotide and protein sequences. These compositions are useful in the diagnosis and treatment of, e.g., CD20+ B-cell lymphoma, immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, and systemic lupus erythematosus (SLE) in canines and felines.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080045699 - Interleukin-1 related gene and protein: Disclosed is an interleukin-1 related gene and gene product. In particular, the invention relates to a protein that is highly homologous to known interleukin-1 cytokines, nucleic acid molecules that encode such a protein, antibodies that recognize the protein, and methods for diagnosing conditions related to host inflammatory and immune responses.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080045701 - Human monoclonal antibody having fat-reducing effect: A purified polypeptide having an amino acid sequence that is substantial identical with the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3, or both, in which the polypeptide binds low density lipoproteins (LDL) or oxidized LDL (oxLDL), or both, and particularly binds well to LDL cholesterol and oxidized... Agent: Pillsbury Winthrop Shaw Pittman LLP

20080039611 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080039612 - Attachment and elaboration strategies for inverse peptide synthesis: i

20080033147 - Method for producing acylated peptides: The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent.... Agent: Novo Nordisk, Inc. Patent Department

20080033148 - Anti-il-tif antibodies and methods of using in inflammation: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases,... Agent: Zymogenetics, Inc. Intellectual Property Department

20080033149 - Human anti-tnf antibodies and peptides: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080033150 - Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis... Agent: Stephen P. Gilbert, Esq. Bryan Cave LLP

20080033151 - Ribonucleases and methods of making them recombinantly: Methods for recombinantly producing new RNases, as well as previously-known RNases, are disclosed. The new RNases are active against human carcinoma cells.... Agent: Mark H. Jay, P.A.

20080033152 - Three-phase partitioning method for purifying a protein: The present invention is a kit and method for purifying a protein of interest.... Agent: Licata & Tyrrell P.C.